|
Samaritan Kicks Off Follow-On HIV Study |
|
|
|
10 Mar 2006 |
LAS VEGAS, NV, USA | March 09, 2006 | Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, it is starting a second Phase II monotherapy trial, of its lead oral entry inhibitor anti-viral agent SP01A, in treatment experienced HIV-infected patients.
Dr. Thomas Lang, Samaritan's Chief Drug Development Officer stated, "We have completed enrollment for our first monotherapy trial and the start of this second trial means we have cleared another important milestone in SP01A's development path
Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A. As we successful complete each of these FDA milestones, it completely strengthens our belief in SP01A as a life-saving drug for HIV drug resistant patients."
The trial is a multi-center, double blind, randomized, placebo-controlled, study of orally administered SP01A as monotherapy, in HIV-infected patients. This trial is designed to accrue treatment-experienced HIV patients that are failing on their current anti-viral therapy. Patients are entered into a 2-week washout phase followed by 28 days of monotherapy treatment with SP01A. The primary analysis for the study is the reduction in viral load (log10) in SP01A active arms and a placebo arm, as measured from Baseline to Study-End.
For more information on this clinical trial, please go to the FDA Clinical Trials Website at http://www.clinicaltrial.gov/ct/show/NCT00299897?order=1
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Look at www.samaritanpharma.com. Please register on our website so we can notify you of upcoming conference calls, news and events. http://www.samaritanpharma.com/media/signup.html
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.
Contact:
Samaritan Pharmaceuticals, Inc.
Gene Boyle, 702-735-7001
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
SOURCE: Samaritan Pharmaceuticals, Inc |
